WASHINGTON REPORT
DOT CBD Notice U.S. Department of Transportation sent this bulletin at 02/18/2020 10:00 AM EST
DOT OFFICE OF DRUG AND ALCOHOL POLICY AND COMPLIANCE NOTICE
Te Agricultural Improvement Act of 2018, Pub. L. 115-334, (Farm Bill) removed hemp from the definition of marijuana under the Controlled Substances Act. Under the Farm Bill, hemp-derived products containing a concentration of up to 0.3% tetrahydrocannabinol (THC) are not controlled substances. THC is the primary psychoactive component of marijuana. Any product, including “Cannabidiol” (CBD) products, with a concentration of more than 0.3% THC remains classified as marijuana, a Schedule I drug under the Controlled Substances Act. We have had inquiries about whether
the Department of Transportation- regulated safety-sensitive employees can use CBD products. Safety-sensitive employees who are subject to drug testing specified under 49 CFR part 40 (Part 40) include: pilots, school bus drivers, truck drivers, train engineers, transit vehicle operators, aircraſt maintenance personnel, fire-armed transit security personnel, ship captains, and pipeline emergency response personnel, among others. It is important for all employers and
safety-sensitive employees to know: 1. Te Department of Transportation requires testing for marijuana and not CBD.
For additional information, please visit:
[i]* What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD: The FDA is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.”
https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what- were-working-find-out-about-products-containing-cannabis-or-cannabis
**
https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products https://content.govdelivery.com/attachments/USDOT/2020/02/14/file_attachments/1379861/ODAPC%20CBD%20Notice.pdf
30 datia focus 2020 • Issue 2
2. Te labeling of many CBD products may be misleading because the products could contain higher levels of THC than what the product label states. Te Food and Drug Administration (FDA) does not currently certify the levels of THC in CBD products, so there is no Federal oversight to ensure that the labels are accurate. Te FDA has cautioned the public that: “Consumers should beware purchasing and using any [CBD] products.” Te FDA has stated: “It is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.”* Also, the FDA has issued several warning leters to companies because their products contained more CBD than indicated on the product label. **[i]
3. Te Department of Transportation’s Drug and Alcohol Testing Regulation, Part 40, does not authorize the use of Schedule I drugs, including marijuana, for any reason. Furthermore, CBD use is not a legitimate medical explanation for a laboratory-confirmed marijuana positive result. Terefore, Medical Review Officers will verify a drug test confirmed at the appropriate cutoffs as positive, even if an
employee claims they only used a CBD product.
It remains unacceptable for any
safety-sensitive employee subject to the Department of Transportation’s drug testing regulations to use marijuana. Since the use of CBD products could lead to a positive drug test result, Department of Transportation-regulated safety-sensitive employees should exercise caution when considering whether to use CBD products. Te contents of this document do not
have the force and effect of law and are not meant to bind the public in any way. Tis document is intended only to provide clarity to the public regarding existing requirements under the law or agency policies. Tis policy and compliance notice is not legally binding in its own right and will not be relied upon by the Department as a separate basis for affirmative enforcement action or other administrative penalty. Conformity with this policy and compliance notice is voluntary only and nonconformity will not affect rights and obligations under existing statutes and regulations. Safety-sensitive employees must continue to comply with the underlying regulatory requirements for drug testing, specified at 49 CFR part 40.
February 18, 2020
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
